Clinical Trial: Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07356466) titled 'Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma' on Dec. 21, 2025.

Brief Summary: The purpose of this study is to evaluate the objective response rate (ORR) of Pembrolizumab combined with Lenvatinib and SOX compared with SOX alone in the treatment of patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma.

Study Start Date: May 01, 2025

Study Type: INTERVENTIONAL

Condition: Gastric (Stomach) Cancer

Intervention: DRUG: Pucotenlimab Combined with Lenvatinib

Pucotenlimab...